;PMID: 8818577
;source_file_1918.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..158] = [t:47..158]
;2)section:[e:162..186] = [t:162..186]
;3)section:[e:190..281] = [t:190..281]
;4)sentence:[e:285..368] = [t:285..368]
;5)sentence:[e:369..486] = [t:369..486]
;6)sentence:[e:487..645] = [t:487..645]
;7)sentence:[e:646..910] = [t:646..910]
;8)sentence:[e:911..1095] = [t:911..1095]
;9)sentence:[e:1096..1322] = [t:1096..1322]
;10)sentence:[e:1323..1497] = [t:1323..1497]
;11)sentence:[e:1498..1735] = [t:1498..1735]
;12)sentence:[e:1736..1923] = [t:1736..1923]
;13)sentence:[e:1924..2031] = [t:1924..2031]
;14)sentence:[e:2032..2245] = [t:2032..2245]
;15)sentence:[e:2246..2448] = [t:2246..2448]
;16)section:[e:2452..2496] = [t:2452..2496]
;Token/POS Errors
;ERROR_Token in entity file but not tree[1274..1278] P450
;ERROR_Token in entity file but not tree[1278..1281] 1A2
;ERROR_Token in entity file but not tree[2073..2077] P450
;ERROR_Token in entity file but not tree[2077..2080] 2D6
;ERROR_Token in tree file but not entity[1274..1281] P4501A2
;ERROR_Token in tree file but not entity[2073..2080] P4502D6

;section 0 Span:0..41
;Drug Metab Dispos. 1996 Jul;24(7):786-91.
(SEC
  (FRAG (NNP:[0..4] Drug) (NNP:[5..10] Metab) (NNP:[11..17] Dispos)
        (.:[17..18] .) (CD:[19..23] 1996) (.:[24..29] Jul;2) (::[29..31] 4-LRB-)
        (CD:[31..32] 7) (-RRB-:[32..33] -RRB-) (CD:[33..40] :786-91)
        (.:[40..41] .)))

;sentence 1 Span:47..158
;Identification of human liver cytochrome P450 isoforms involved in the in
;vitro  metabolism of cyclobenzaprine.
;[77..101]:cyp450:"cytochrome P450 isoforms"
;[142..157]:substance:"cyclobenzaprine"
(SENT
  (NP-HLN
    (NP (NN:[47..61] Identification))
    (PP (IN:[62..64] of)
      (NP
        (NP (JJ:[65..70] human) (NN:[71..76] liver)
          
          (NML (NN:[77..87] cytochrome) (NN:[88..92] P450))
          (NNS:[93..101] isoforms))
        (VP (VBN:[102..110] involved)
          (NP (-NONE-:[110..110] *))
          (PP-CLR (IN:[111..113] in)
            (NP
              (NP (DT:[114..117] the)
                (ADJP (FW:[118..120] in) (FW:[121..126] vitro))
                (NN:[128..138] metabolism))
              (PP (IN:[139..141] of)
                (NP (NN:[142..157] cyclobenzaprine))))))))
    (.:[157..158] .)))

;section 2 Span:162..186
;Wang RW, Liu L, Cheng H.
(SEC
  (FRAG (NNP:[162..166] Wang) (NNP:[167..169] RW) (,:[169..170] ,)
        (NNP:[171..174] Liu) (NNP:[175..177] L,) (NNP:[178..183] Cheng)
        (NNP:[184..186] H.)))

;section 3 Span:190..281
;Department of Drug Metabolism, Merck Research Laboratories, Rahway, New
;Jersey  07065, USA.
(SEC
  (FRAG (NNP:[190..200] Department) (IN:[201..203] of) (NNP:[204..208] Drug)
        (NNP:[209..219] Metabolism) (,:[219..220] ,) (NNP:[221..226] Merck)
        (NNP:[227..235] Research) (NNP:[236..248] Laboratories) (,:[248..249] ,)
        (NNP:[250..256] Rahway) (,:[256..257] ,) (NNP:[258..261] New)
        (NNP:[262..268] Jersey) (CD:[270..275] 07065) (,:[275..276] ,)
        (NNP:[277..280] USA) (.:[280..281] .)))

;sentence 4 Span:285..368
;Cyclobenzaprine (Flexeril) is a muscle relaxant, possessing a tricyclic 
;structure.
;[285..300]:substance:"Cyclobenzaprine"
;[302..310]:substance:"Flexeril"
;[324..332]:substance:"relaxant"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[285..300] Cyclobenzaprine))
      (NP (-LRB-:[301..302] -LRB-) (NNP:[302..310] Flexeril)
          (-RRB-:[310..311] -RRB-)))
    (VP (VBZ:[312..314] is)
      (NP-PRD
        (NP (DT:[315..316] a) (NN:[317..323] muscle) (NN:[324..332] relaxant))
        (,:[332..333] ,)
        (VP (VBG:[334..344] possessing)
          (NP (DT:[345..346] a) (JJ:[347..356] tricyclic)
              (NN:[358..367] structure)))))
    (.:[367..368] .)))

;sentence 5 Span:369..486
;Numerous therapeutic agents containing this structure are known to be 
;metabolized by polymorphic cytochrome P4502D6.
;[378..396]:substance:"therapeutic agents"
;[467..485]:cyp450:"cytochrome P4502D6"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[369..377] Numerous)
         (JJ:[378..389] therapeutic) (NNS:[390..396] agents))
      (VP (VBG:[397..407] containing)
        (NP (DT:[408..412] this) (NN:[413..422] structure))))
    (VP (VBP:[423..426] are)
      (VP (VBN:[427..432] known)
        (S
          (NP-SBJ-1 (-NONE-:[432..432] *))
          (VP (TO:[433..435] to)
            (VP (VB:[436..438] be)
              (VP (VBN:[440..451] metabolized)
                (NP-1 (-NONE-:[451..451] *))
                (PP (IN:[452..454] by)
                  (NP-LGS (JJ:[455..466] polymorphic)
                     (NN:[467..477] cytochrome) (NN:[478..485] P4502D6)))))))))
    (.:[485..486] .)))

;sentence 6 Span:487..645
;The aim of this study was to  determine if cytochrome P4502D6 and other
;isoforms are involved in the  metabolism of cyclobenzaprine in human liver
;microsomes.
;[530..548]:cyp450:"cytochrome P4502D6"
;[559..567]:cyp450:"isoforms"
;[603..618]:substance:"cyclobenzaprine"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[487..490] The) (NN:[491..494] aim))
      (PP (IN:[495..497] of)
        (NP (DT:[498..502] this) (NN:[503..508] study))))
    (VP (VBD:[509..512] was)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[512..512] *))
        (VP (TO:[513..515] to)
          (VP (VB:[517..526] determine)
            (SBAR (IN:[527..529] if)
              (S
                (NP-SBJ-1
                  (NP (NN:[530..540] cytochrome) (NN:[541..548] P4502D6))
                  (CC:[549..552] and)
                  (NP (JJ:[553..558] other) (NNS:[559..567] isoforms)))
                (VP (VBP:[568..571] are)
                  (VP (VBN:[572..580] involved)
                    (NP-1 (-NONE-:[580..580] *))
                    (PP-CLR (IN:[581..583] in)
                      (NP
                        (NP (DT:[584..587] the) (NN:[589..599] metabolism))
                        (PP (IN:[600..602] of)
                          (NP (NN:[603..618] cyclobenzaprine)))))
                    (PP-LOC (IN:[619..621] in)
                      (NP (JJ:[622..627] human) (NN:[628..633] liver)
                          (NNS:[634..644] microsomes)))))))))))
    (.:[644..645] .)))

;sentence 7 Span:646..910
;Selective cytochrome  P450 inhibitors for CYP1A1/2 (furafylline and
;7,8-benzoflavone) and CYP3A4  (troleandomycin, gestodene, and ketoconazole)
;inhibited the formation of  desmethylcyclobenzaprine, a major metabolite of
;cyclobenzaprine, in human liver  microsomes.
;[656..672]:cyp450:"cytochrome  P450"
;[673..683]:substance:"inhibitors"
;[688..694]:cyp450:"CYP1A1"
;[688..693]...[695..696]:cyp450:"CYP1A"..."2"
;[698..709]:substance:"furafylline"
;[714..730]:substance:"7,8-benzoflavone"
;[736..742]:cyp450:"CYP3A4"
;[745..759]:substance:"troleandomycin"
;[761..770]:substance:"gestodene"
;[776..788]:substance:"ketoconazole"
;[818..842]:substance:"desmethylcyclobenzaprine"
;[852..862]:substance:"metabolite"
;[866..881]:substance:"cyclobenzaprine"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[646..655] Selective)
        (NML (NN:[656..666] cytochrome) (NN:[668..672] P450))
        (NNS:[673..683] inhibitors))
      (PP (IN:[684..687] for)
        (NP
          (NP
            (NP
              (NML-1 (NN:[688..693] CYP1A))
              (CD:[693..694] 1))
            (SYM:[694..695] /)
            (NP
              (NML-1 (-NONE-:[695..695] *P*))
              (CD:[695..696] 2))
            (PRN (-LRB-:[697..698] -LRB-)
              (NP (NN:[698..709] furafylline) (CC:[710..713] and)
                  (NN:[714..730] 7,8-benzoflavone))
              (-RRB-:[730..731] -RRB-)))
          (CC:[732..735] and)
          (NP (NN:[736..742] CYP3A4)
            (PRN (-LRB-:[744..745] -LRB-)
              (NP (NN:[745..759] troleandomycin) (,:[759..760] ,)
                  (NN:[761..770] gestodene) (,:[770..771] ,) (CC:[772..775] and)
                  (NN:[776..788] ketoconazole))
              (-RRB-:[788..789] -RRB-))))))
    (VP (VBD:[790..799] inhibited)
      (NP
        (NP (DT:[800..803] the) (NN:[804..813] formation))
        (PP (IN:[814..816] of)
          (NP
            (NP (NN:[818..842] desmethylcyclobenzaprine))
            (,:[842..843] ,)
            (NP
              (NP (DT:[844..845] a) (JJ:[846..851] major)
                  (NN:[852..862] metabolite))
              (PP (IN:[863..865] of)
                (NP (NN:[866..881] cyclobenzaprine)))))))
      (,:[881..882] ,)
      (PP-LOC (IN:[883..885] in)
        (NP (JJ:[886..891] human) (NN:[892..897] liver)
            (NNS:[899..909] microsomes))))
    (.:[909..910] .)))

;sentence 8 Span:911..1095
;Antibodies directed against CYP1A1/2 and CYP3A4 inhibited the  demethylation
;reaction whereas anti-human CYP2C9/10, CYP2C19, and CYP2E1  antibodies did
;not show any inhibitory effects.
;[911..921]:substance:"Antibodies"
;[939..945]:cyp450:"CYP1A1"
;[939..944]...[946..947]:cyp450:"CYP1A"..."2"
;[952..958]:cyp450:"CYP3A4"
;[1005..1022]...[1048..1058]:substance:"anti-human CYP2C9"..."antibodies"
;[1005..1021]...[1023..1025]...[1048..1058]:substance:"anti-human
;CYP2C"..."10"..."antibodies"
;[1005..1015]...[1040..1058]:substance:"anti-human"..."CYP2E1  antibodies"
;[1005..1015]...[1027..1034]...[1048..1058]:substance:"anti-human"..."CYP2C19"
;..."antibodies"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[911..921] Antibodies))
      (VP (VBN:[922..930] directed)
        (NP (-NONE-:[930..930] *))
        (PP (IN:[931..938] against)
          (NP
            (NP
              (NP
                (NML-5 (NN:[939..944] CYP1A))
                (CD:[944..945] 1))
              (SYM:[945..946] /)
              (NP
                (NML-5 (-NONE-:[946..946] *P*))
                (CD:[946..947] 2)))
            (CC:[948..951] and)
            (NP (NN:[952..958] CYP3A4))))))
    (VP (VBD:[959..968] inhibited)
      (NP (DT:[969..972] the) (NN:[974..987] demethylation)
          (NN:[988..996] reaction))
      (SBAR-ADV (IN:[997..1004] whereas)
        (S
          (NP-SBJ
            (NP
              (NP
                (NML
                  (ADJP-3 (AFX:[1005..1009] anti) (HYPH:[1009..1010] -)
                          (JJ:[1010..1015] human))
                  (NML-1 (NN:[1016..1021] CYP2C))
                  (CD:[1021..1022] 9))
                (NML-4 (-NONE-:[1022..1022] *P*)))
              (SYM:[1022..1023] /)
              (NP
                (NML
                  (ADJP-3 (-NONE-:[1023..1023] *P*))
                  (NML-1 (-NONE-:[1023..1023] *P*))
                  (CD:[1023..1025] 10))
                (NML-4 (-NONE-:[1025..1025] *P*))))
            (,:[1025..1026] ,)
            (NP
              (NML
                (ADJP-3 (-NONE-:[1026..1026] *P*))
                (NN:[1027..1034] CYP2C19))
              (NML-4 (-NONE-:[1034..1034] *P*)))
            (,:[1034..1035] ,) (CC:[1036..1039] and)
            (NP
              (ADJP-3 (-NONE-:[1039..1039] *P*))
              (NN:[1040..1046] CYP2E1)
              (NML-4 (NNS:[1048..1058] antibodies))))
          (VP (VBD:[1059..1062] did) (RB:[1063..1066] not)
            (VP (VB:[1067..1071] show)
              (NP (DT:[1072..1075] any) (JJ:[1076..1086] inhibitory)
                  (NNS:[1087..1094] effects)))))))
    (.:[1094..1095] .)))

;sentence 9 Span:1096..1322
;When a panel of microsomes  prepared from human B-lymphoblastoid cells that
;expressed specific human  cytochrome P450 isoforms were used, only microsomes
;containing cytochromes  P4501A2, 2D6, and 3A4 catalyzed N-demethylation.
;[1198..1222]:cyp450:"cytochrome P450 isoforms"
;[1261..1281]:cyp450:"cytochromes  P4501A2"
;[1261..1278]...[1292..1295]:cyp450:"cytochromes  P450"..."3A4"
;[1261..1278]...[1283..1286]:cyp450:"cytochromes  P450"..."2D6"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-4 (WRB:[1096..1100] When))
      (S
        (NP-SBJ-3
          (NP (DT:[1101..1102] a) (NN:[1103..1108] panel))
          (PP (IN:[1109..1111] of)
            (NP
              (NP (NNS:[1112..1122] microsomes))
              (VP (VBN:[1124..1132] prepared)
                (NP (-NONE-:[1132..1132] *))
                (PP (IN:[1133..1137] from)
                  (NP
                    (NP (JJ:[1138..1143] human)
                        (JJ:[1144..1160] B-lymphoblastoid)
                        (NNS:[1161..1166] cells))
                    (SBAR
                      (WHNP-2 (WDT:[1167..1171] that))
                      (S
                        (NP-SBJ-2 (-NONE-:[1171..1171] *T*))
                        (VP (VBD:[1172..1181] expressed)
                          (NP (JJ:[1182..1190] specific) (JJ:[1191..1196] human)
                            
                            (NML (NN:[1198..1208] cytochrome)
                                 (NN:[1209..1213] P450))
                            (NNS:[1214..1222] isoforms)))))))))))
        (VP (VBD:[1223..1227] were)
          (VP (VBN:[1228..1232] used)
            (NP-3 (-NONE-:[1232..1232] *))
            (ADVP-TMP-4 (-NONE-:[1232..1232] *T*))))))
    (,:[1232..1233] ,)
    (NP-SBJ
      (NP (RB:[1234..1238] only) (NNS:[1239..1249] microsomes))
      (VP (VBG:[1250..1260] containing)
        (NP
          (NP
            (NML-1 (NNS:[1261..1272] cytochromes))
            (NN:[1274..1281] P4501A2))
          (,:[1281..1282] ,)
          (NP
            (NML-1 (-NONE-:[1282..1282] *P*))
            (NN:[1283..1286] 2D6))
          (,:[1286..1287] ,) (CC:[1288..1291] and)
          (NP
            (NML-1 (-NONE-:[1291..1291] *P*))
            (NN:[1292..1295] 3A4)))))
    (VP (VBD:[1296..1305] catalyzed)
      (NP (NN:[1306..1321] N-demethylation)))
    (.:[1321..1322] .)))

;sentence 10 Span:1323..1497
;In addition, demethylation  catalyzed by these recombinant cytochromes P450
;can be completely inhibited with  selective inhibitors at concentrations as
;low as 1 to 20 microM.
;[1382..1398]:cyp450:"cytochromes P450"
;[1443..1453]:substance:"inhibitors"
;[1482..1489]:quantitative-value:"1 to 20"
;[1490..1496]:quantitative-units:"microM"
(SENT
  (S
    (PP (IN:[1323..1325] In)
      (NP (NN:[1326..1334] addition)))
    (,:[1334..1335] ,)
    (NP-SBJ-1
      (NP (NN:[1336..1349] demethylation))
      (VP (VBN:[1351..1360] catalyzed)
        (NP (-NONE-:[1360..1360] *))
        (PP (IN:[1361..1363] by)
          (NP-LGS (DT:[1364..1369] these) (JJ:[1370..1381] recombinant)
             (NNS:[1382..1393] cytochromes) (NN:[1394..1398] P450)))))
    (VP (MD:[1399..1402] can)
      (VP (VB:[1403..1405] be)
        (ADVP (RB:[1406..1416] completely))
        (VP (VBN:[1417..1426] inhibited)
          (NP-1 (-NONE-:[1426..1426] *))
          (PP-MNR (IN:[1427..1431] with)
            (NP (JJ:[1433..1442] selective) (NNS:[1443..1453] inhibitors)))
          (PP (IN:[1454..1456] at)
            (NP
              (NP (NNS:[1457..1471] concentrations))
              (ADJP
                (ADJP (RB:[1472..1474] as) (JJ:[1475..1478] low))
                (PP (IN:[1479..1481] as)
                  (NP
                    (QP (CD:[1482..1483] 1) (TO:[1484..1486] to)
                        (CD:[1487..1489] 20))
                    (NN:[1490..1496] microM)))))))))
    (.:[1496..1497] .)))

;sentence 11 Span:1498..1735
;Interestingly,  cyclobenzaprine N-demethylation was significantly correlated
;with caffeine  3-demethylation (1A2) and testosterone 6 beta-hydroxylation
;(3A4) but not with  dextromethorphan O-demethylation (2D6) in human liver
;microsomes.
;[1514..1529]:substance:"cyclobenzaprine"
;[1580..1588]:substance:"caffeine"
;[1607..1610]:cyp450:"1A2"
;[1616..1628]:substance:"testosterone"
;[1651..1654]:cyp450:"3A4"
;[1670..1686]:substance:"dextromethorphan"
;[1704..1707]:cyp450:"2D6"
(SENT
  (S
    (ADVP (RB:[1498..1511] Interestingly))
    (,:[1511..1512] ,)
    (NP-SBJ-1 (NN:[1514..1529] cyclobenzaprine)
              (NN:[1530..1545] N-demethylation))
    (VP (VBD:[1546..1549] was)
      (VP
        (VP
          (ADVP (RB:[1550..1563] significantly))
          (VBN:[1564..1574] correlated)
          (NP-1 (-NONE-:[1574..1574] *))
          (PP-CLR=2 (IN:[1575..1579] with)
            (NP
              (NP (NN:[1580..1588] caffeine) (NN:[1590..1605] 3-demethylation)
                (PRN (-LRB-:[1606..1607] -LRB-)
                  (NP (NN:[1607..1610] 1A2))
                  (-RRB-:[1610..1611] -RRB-)))
              (CC:[1612..1615] and)
              (NP (NN:[1616..1628] testosterone) (CD:[1629..1630] 6)
                  (NN:[1631..1649] beta-hydroxylation)
                (PRN (-LRB-:[1650..1651] -LRB-)
                  (NP (NN:[1651..1654] 3A4))
                  (-RRB-:[1654..1655] -RRB-))))))
        (CC:[1656..1659] but)
        (VP (RB:[1660..1663] not)
          (PP-CLR=2 (IN:[1664..1668] with)
            (NP (NN:[1670..1686] dextromethorphan)
                (NN:[1687..1702] O-demethylation)
              (PRN (-LRB-:[1703..1704] -LRB-)
                (NP (NN:[1704..1707] 2D6))
                (-RRB-:[1707..1708] -RRB-)))))
        (PP-LOC (IN:[1709..1711] in)
          (NP (JJ:[1712..1717] human) (NN:[1718..1723] liver)
              (NNS:[1724..1734] microsomes)))))
    (.:[1734..1735] .)))

;sentence 12 Span:1736..1923
;To further  determine the involvement of cytochrome P4502D6 in
;cyclobenzaprine metabolism,  liver microsomes from a human that lacked CYP2D6
;enzyme activities was included  in this study.
;[1777..1795]:cyp450:"cytochrome P4502D6"
;[1799..1814]:substance:"cyclobenzaprine"
;[1870..1883]:cyp450:"CYP2D6 enzyme"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[1736..1736] *))
      (VP (TO:[1736..1738] To)
        (ADVP (RBR:[1739..1746] further))
        (VP (VB:[1748..1757] determine)
          (NP
            (NP (DT:[1758..1761] the) (NN:[1762..1773] involvement))
            (PP (IN:[1774..1776] of)
              (NP (NN:[1777..1787] cytochrome) (NN:[1788..1795] P4502D6)))
            (PP (IN:[1796..1798] in)
              (NP (NN:[1799..1814] cyclobenzaprine) (NN:[1815..1825] metabolism)))))))
    (,:[1825..1826] ,)
    (NP-SBJ-2
      (NP (NN:[1828..1833] liver) (NNS:[1834..1844] microsomes))
      (PP (IN:[1845..1849] from)
        (NP
          (NP (DT:[1850..1851] a) (NN:[1852..1857] human))
          (SBAR
            (WHNP-1 (WDT:[1858..1862] that))
            (S
              (NP-SBJ-1 (-NONE-:[1862..1862] *T*))
              (VP (VBD:[1863..1869] lacked)
                (NP
                   (NN:[1870..1876] CYP2D6) (NN:[1877..1883] enzyme)
                  (NNS:[1884..1894] activities))))))))
    (VP (VBD:[1895..1898] was)
      (VP (VBN:[1899..1907] included)
        (NP-2 (-NONE-:[1907..1907] *))
        (PP-CLR (IN:[1909..1911] in)
          (NP (DT:[1912..1916] this) (NN:[1917..1922] study)))))
    (.:[1922..1923] .)))

;sentence 13 Span:1924..2031
;The data showed that cyclobenzaprine N-demethylation still  occurred in the
;incubation with this microsome.
;[1945..1960]:substance:"cyclobenzaprine"
(SENT
  (S
    (NP-SBJ (DT:[1924..1927] The) (NNS:[1928..1932] data))
    (VP (VBD:[1933..1939] showed)
      (SBAR (IN:[1940..1944] that)
        (S
          (NP-SBJ (NN:[1945..1960] cyclobenzaprine)
                  (NN:[1961..1976] N-demethylation))
          (ADVP (RB:[1977..1982] still))
          (VP (VBD:[1984..1992] occurred)
            (PP-LOC (IN:[1993..1995] in)
              (NP
                (NP (DT:[1996..1999] the) (NN:[2000..2010] incubation))
                (PP (IN:[2011..2015] with)
                  (NP (DT:[2016..2020] this) (NN:[2021..2030] microsome)))))))))
    (.:[2030..2031] .)))

;sentence 14 Span:2032..2245
;These results suggested that  cytochrome P4502D6 plays only a minor role in
;cyclobenzaprine N-demethylation  whereas 3A4 and 1A2 are primarily
;responsible for cyclobenzaprine metabolism in  human liver microsomes.
;[2062..2080]:cyp450:"cytochrome P4502D6"
;[2062..2077]...[2157..2160]:cyp450:"cytochrome P450"..."1A2"
;[2062..2077]...[2149..2152]:cyp450:"cytochrome P450"..."3A4"
;[2108..2123]:substance:"cyclobenzaprine"
;[2191..2206]:substance:"cyclobenzaprine"
(SENT
  (S
    (NP-SBJ (DT:[2032..2037] These) (NNS:[2038..2045] results))
    (VP (VBD:[2046..2055] suggested)
      (SBAR (IN:[2056..2060] that)
        (S
          (NP-SBJ (NN:[2062..2072] cytochrome) (NN:[2073..2080] P4502D6))
          (VP (VBZ:[2081..2086] plays)
            (NP (RB:[2087..2091] only) (DT:[2092..2093] a)
                (JJ:[2094..2099] minor) (NN:[2100..2104] role))
            (PP (IN:[2105..2107] in)
              (NP (NN:[2108..2123] cyclobenzaprine)
                  (NN:[2124..2139] N-demethylation)))
            (SBAR-ADV (IN:[2141..2148] whereas)
              (S
                (NP-SBJ (NN:[2149..2152] 3A4) (CC:[2153..2156] and)
                        (NN:[2157..2160] 1A2))
                (VP (VBP:[2161..2164] are)
                  (ADVP (RB:[2165..2174] primarily))
                  (ADJP-PRD (JJ:[2175..2186] responsible)
                    (PP (IN:[2187..2190] for)
                      (NP
                        (NP (NN:[2191..2206] cyclobenzaprine)
                            (NN:[2207..2217] metabolism))
                        (PP-LOC (IN:[2218..2220] in)
                          (NP (JJ:[2222..2227] human) (NN:[2228..2233] liver)
                              (NNS:[2234..2244] microsomes)))))))))))))
    (.:[2244..2245] .)))

;sentence 15 Span:2246..2448
;Due to the minimum involvement of CYP2D6 in the vitro  metabolism of
;cyclobenzaprine, the polymorphism of cytochrome P4502D6 in man  should not be
;of muci concern in the clinical use of cyclobenzaprine.
;[2280..2286]:cyp450:"CYP2D6"
;[2315..2330]:substance:"cyclobenzaprine"
;[2352..2370]:cyp450:"cytochrome P4502D6"
;[2432..2447]:substance:"cyclobenzaprine"
(SENT
  (S
    (PP (IN:[2246..2249] Due)
      (PP (TO:[2250..2252] to)
        (NP
          (NP (DT:[2253..2256] the) (JJ:[2257..2264] minimum)
              (NN:[2265..2276] involvement))
          (PP (IN:[2277..2279] of)
            (NP (NN:[2280..2286] CYP2D6)))
          (PP-LOC (IN:[2287..2289] in)
            (NP
              (NP (DT:[2290..2293] the) (FW:[2294..2299] vitro)
                  (NN:[2301..2311] metabolism))
              (PP (IN:[2312..2314] of)
                (NP (NN:[2315..2330] cyclobenzaprine))))))))
    (,:[2330..2331] ,)
    (NP-SBJ
      (NP (DT:[2332..2335] the) (NN:[2336..2348] polymorphism))
      (PP (IN:[2349..2351] of)
        (NP (NN:[2352..2362] cytochrome) (NN:[2363..2370] P4502D6)))
      (PP-LOC (IN:[2371..2373] in)
        (NP (NN:[2374..2377] man))))
    (VP (MD:[2379..2385] should) (RB:[2386..2389] not)
      (VP (VB:[2390..2392] be)
        (PP-PRD (IN:[2393..2395] of)
          (NP (JJ:[2396..2400] muci) (NN:[2401..2408] concern)))
        (PP (IN:[2409..2411] in)
          (NP
            (NP (DT:[2412..2415] the) (JJ:[2416..2424] clinical)
                (NN:[2425..2428] use))
            (PP (IN:[2429..2431] of)
              (NP (NN:[2432..2447] cyclobenzaprine)))))))
    (.:[2447..2448] .)))

;section 16 Span:2452..2496
;PMID: 8818577 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2452..2456] PMID) (::[2456..2457] :) (CD:[2458..2465] 8818577)
        (NN:[2466..2467] -LSB-) (NNP:[2467..2473] PubMed) (::[2474..2475] -)
        (NN:[2476..2483] indexed) (IN:[2484..2487] for)
        (NNP:[2488..2496] MEDLINE-RSB-)))
